Correlation of CD24 expression with Histological Grades of Papillary Urothelial Carcinoma
DOI:
https://doi.org/10.69980/ajpr.v28i1.639Keywords:
Cluster of Differentiations (CD), Immunohistochemistry (IHC), Papillary Urothelial Carcinoma (PUC), Transurethral Resection of Urinary Bladder Tumor (TURBT)Abstract
Background: Although the ratio of urinary bladder carcinoma is lowest in female than male, but in earlier sex it’s grow in higher violent form of lesion, usually present at higher complex stage and poor outcome than later sex. The commonest histopathological sub-type of urinary bladder neoplasm is urothelial carcinoma. According to resent guidelines of European Association of Urology and Japanese Urology Association urothelial carcinoma of any variants are measured as high grade still if no muscular invasion.
Objective: To observe the correlation between CD-24 expressions with various histological grades of Papillary Urothelial Carcinoma at Tertiary Care Hospital Karachi
Material and Methods: This cross sectional study was conducted in the department of Pathology Basic Medical Sciences Institute (BMSI), JPMC Karachi. Amongst 83 selected cases of papillary urothelial carcinoma was reviewed and morphological diagnosis done on Hematoxylin and Eosin (H&E). Histological grading were categorized and CD-24 immuno staining done. The data analyzed by SPSS version 21.
Results: Out of 83 cases 38.5%, 37.5% and 24% cases showed invasive, high and low gradePUC respectively. In male gender 39%, 35% and 26% cases were noted in high, invasive and low grade, while amongst female 48%, 33% and19% cases were in invasive, high and low grade respectively. Most cases showing high grade and invasive tumors were noted in 5th and 6th decades. CD-24 immuno staining positivity was seen in majority of high grade and invasive PUC. In high grade 68% showed moderate and 13% showed strong immuno staining. In invasive 53% showed moderate, 31% strong positivity. Whereas 45% cases in low grade were immuno negative.
Conclusion: Majority of low grade cases of PUC were negative for CD-24 immuno staining, while 81% in high grade and 84% in invasive variant showed moderate to strong immuno staining. The intensity of CD-24 expression increased with the higher histological grades of Papillary Urothelial Carcinoma, which indicating that the CD-24 is a marker of poor prognosis.
References
1. Hanif M, Zaidi P, Kamal S, Hameed A. Institution-based cancer incidence in a local population in Pakistan: Nine years data analysis. Asian Pacific Jr of Can Prev, 2009; (10): 227-230.
2. Overdevest JB, Knubel KH, Duex JE, Thomas S, Nitz MD,Harding MA et al. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc Nati Acad Sci USA. 2012; 109 (51):3588-3596. DOI. 10.1073/pnas. 113960109.
3. Grippo PJ, and Sandgren EP. Highly invasive Transitional cell carcinoma of bladder in Simian Virus 40 T-antigen transgenic mouse model. American Jr of Pathol, 2000; 157 (3): 805-813.
4. Salehi A, Khezri AA, Malekmakan L, and Aminsharifi A. Epidemiologic status of bladder cancer in Shiraz Southern Iran. Asian Pacific Jrof can prev, 2011; 12: 1323-1327.
5. Bakir WA, Abed DW, andUllateef AYA. The relationship between Bcl-2 and P53 proteins in transitional cell carcinoma of bladder. Available i j c mg @ iccmgr.com. Iraqi Jr of cancer and med Gene, 2011; (4): 1-5.
6. Emily Gill and Claire M. Perks. Mini-review: Current bladder cancer treatment. The need for improvement. Int. Jr. Mol. Sci. 2024; 25, 1557: 1-13. https://doi.org/10.3390/ijms25031557.
7. Duygu Enneli and Tolga Baglan. The many faces of urothelial carcinomas: An update from Pathology to clinical approach and challenges in practice. Urology Res and Prac 2023; 49(3): 147-161 DOI: 10.5152/tud.2023.23023
8. Badar F, Sattar A, Meerza F, Irfan N, and Siddiqui N. Carcinoma of the urinary bladder in a Tertiary care setting in a developing country. Asian Pacific Jr of Can Prev, 2009; (10): 499-552.
9. Weintraub MD, Vourganti S, Li Q, Apolo AB, Metwalli AR, and Agarwal PK. Targeting the epidermal growth factor receptor in bladder cancer. JrCarcino Mutag,2013; (4):1-7. DOI- Org/10.4172/ 2157-2158. 1000143.
10. Colombel M, Soloway M, Akaza H, Bohel A, Palou J, Buckley R et al. Epidemiology, Staging, Grading and risk stratification of bladder cancer. Available at www eu-cam.org/europeanurology. European Association of Urology. 2008; 618-626. DOI: 10.1016/ j eursup.
11. Mansoor M, Ali S, Fasihuddin Q,and Baloch MU. Superficial bladder tumors; Recurrence and progression. Jr of Col of Phy and Sur Pak (J of CPSP). 2011; 21 (2):157- 160.
12. Al-Tereihi RG, Kerbel HA, Saheb RH, Al-Janabi AA, Yasseen AA.Over expression HER-2/Neu receptor protein in urinary bladder carcinoma, An immuno histochemical study. Jr Fac Med Baghdad 2011; 53 (2):175-179.
13. Ahmad MR,and Perviz MK. Risk factors of urinary bladder cancer in Peshawar region of Khyber Pakhtoonkhawa. Available at http// www. Ayubmed.edu PK/JAMC/PAST. Jr Ayub med college Abbotabad 2010; 22 (1): 160-163.
14. Rosai J, Ackerman. Surgical pathology. Urinary Tract, Bladder. Elsevier New Delhi India. 10th Ed. 2011; (2): 1317-1343.
15. Fletcher CDM. Diagnostic histopathology of tumor. Tumors of the urinary bladder. Elsevier china 4th Ed. 2013; (2): 601-644.
16. Eble JN. Santer G, Epstein J. Pathology and Genetics’of tumor of the urinary system and male genital organs. Tumors of the urinary bladder. IARC Press Lyon. 2004; (6): 89-154.
17. Enache M, Simionescu CE, Stepan A. EGFR and Her 2/Neu immuno expression in papillary urothelial bladder carcinomas. Rom J Morphol Embryol 2013; 54 (1): 1379-1414
18. Choi YL, Lee SH, Kwon GN, Park CK, Han JJ, Choi JS et al. Over expression of CD24. Association with invasiveness in Urothelial carcinoma of bladder. Arch pathol lab Med. 2007;131 (2): 275-281.
19. Bouris B, Gur HG, Mashin Y, Miler U, Gur E, Inbar R et al. First report of screening an asymptomatic population for cancer; the field of an integrated cancer prevention center. Aviv Uni, Ramat Aviv, Israel, IMAJ, 2010; (12): 21-24.
20. Bladder Cancer treatment. Patient / Health professional. National Cancer Institute 2015; pp 01-29.
21. Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival, Available at www.aacr Jr. Org. Jr American Association Cancer Clin Can res. 2005; (11): 6574-6581. DOI:10.1158/1078-0432.CCR-05-0606. .
22. Choi YL, Xuan YH, Lee SJ, Park SM, Kim WJ, Kim HJ et al. Enhanced CD24 expression in colorectal cancer correlates with prognostic factors. Korean J Pathology 2006; (40):103-111.
23. Lia J, Li. C, Yuan .H, Gong. F. Clinical value of CD24 expression in retinoblastoma, Jr Bio Med & Bio Tech, 2012; (10):1-6. ID 158084, 6 pp. Doi: 10.1155/2012/158084.
24. Karahan N, Barut I, Baspinar S, Kapucuoglu N, Tarhan O, Candir O. CD24 expression in colorectal carcinoma. Erciyes Medical Jr. 2008; 30(4): 225-231.
25. Sagiv E, Starr A, Rozovski U, Khosravi R, Altevogt P, Wang T et al. Targeting CD24 for Treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Available at www. aacrjournalsorg. American Association for Ca Res. 2008; 4 (8):2803-2812. DOI:10.1158/ 0008-5472. CAN -07.6463.
26. Kounel S, Kapranos N, Kouri E, Coppola D, Papadaki H, and Jones MW. Immunohistochemical profile of endometrial adenocarcinoma. A Study of 61 cases and review of the literature. United State and CandianAcademu Patho 2000; 13(4):378-388.
27. Biswas RR, Mangal S, Guha D, Basu K, and Karmakar D. An Epidemiological study of cases of urothelial carcinoma of urinary bladder in a Tertiary care center. Jr of Krishna Institute of Med Sci Uni, 2013; 2 (1): 82-88. ISSN 2231-4261.
28. Zhang HZ, Wang CF, Sun JJ, and Yu BH. A combined clinicopathologic analysis of 658 urothelial carcinoma cases of urinary bladder. Chinese Med Sci Jr, 2012; 27 (1): 24-28.
29. Tripathi A, Folsom AR, and Anderson KE. Risk factors for urinary bladder carcinoma in post menopausal women. American Cancer Society (ACS) 2002; 95: 2316-2323.
30. Liu.C, Zheng S, Shen H, Xu K, Chen J, Li H et al. Clinical significance of CD24 as a predictor of bladder cancer recurrence. Oncology letters 2013; (6): 96-100.DOI;10.3892/ol.2013, 1357.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 American Journal of Psychiatric Rehabilitation
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License permitting all use, distribution, and reproduction in any medium, provided the work is properly cited.
